The course of COVID-19 in a multiple sclerosis: a case report
1
Department of the Heart and Great Vessels Pathology Diagnostics, Heart Institute of the Ministry of Health of Ukraine , Ukraine, Ukraine
2
Department of functional diagnostics, Shupyk National Healthcare University of Ukraine, Ukraine
3
Department of Infectious deseases, Bogomolets National Medical University, Ukraine
Submission date: 2023-07-23
Acceptance date: 2023-11-09
Publication date: 2024-02-23
Corresponding author
Olga Yepanchintseva
Department of the Heart and Great Vessels Pathology Diagnostics, Heart Institute of the Ministry of Health of Ukraine , Ukraine, Bratyslavska str., 5A,, 02660, Кyiv, Ukraine
Department of the Heart and Great Vessels Pathology Diagnostics, Heart Institute of the Ministry of Health of Ukraine , Ukraine, Bratyslavska str., 5A,, 02660, Кyiv, Ukraine
Wiadomości Lekarskie 2024;77(1):166-170
KEYWORDS
TOPICS
ABSTRACT
Aim:
To evaluate the influence of disease-modifying immunotherapy on infectious complications of COVID-19.
Material and methods:
The authors present the case of a prolonged course of COVID 19 disease in a 37-year-old patient with multiple sclerosis on anti-CD20 monoclonal antibodies immunotherapy.
Case report:
This publication presents a clinical case of the course of COVID-19 disease in a multiple sclerosis patient receiving ublituximab therapy. The use of disease-modifying anti-CD20 monoclonal antibody therapy was associated with a protracted wave-like course of COVID-19 with the addition of a bacterial infection. This publication illustrates the key mechanisms and approaches to the treatment of such a cohort of patients.
Summary:
The use of highly effective multiple sclerosis treatment methods may be associated with an increase in the incidence of COVID-19 and worsening of its course. Multiple sclerosis patients receiving anti-CD20 therapy are at particular risk of a wave-like course of COVID-19, caused by immunosuppression, creates a basis for bacterial and fungal coinfection.
To evaluate the influence of disease-modifying immunotherapy on infectious complications of COVID-19.
Material and methods:
The authors present the case of a prolonged course of COVID 19 disease in a 37-year-old patient with multiple sclerosis on anti-CD20 monoclonal antibodies immunotherapy.
Case report:
This publication presents a clinical case of the course of COVID-19 disease in a multiple sclerosis patient receiving ublituximab therapy. The use of disease-modifying anti-CD20 monoclonal antibody therapy was associated with a protracted wave-like course of COVID-19 with the addition of a bacterial infection. This publication illustrates the key mechanisms and approaches to the treatment of such a cohort of patients.
Summary:
The use of highly effective multiple sclerosis treatment methods may be associated with an increase in the incidence of COVID-19 and worsening of its course. Multiple sclerosis patients receiving anti-CD20 therapy are at particular risk of a wave-like course of COVID-19, caused by immunosuppression, creates a basis for bacterial and fungal coinfection.
Share
RELATED ARTICLE
| eISSN: | 2719-342X |
| ISSN: | 0043-5147 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
